319 related articles for article (PubMed ID: 23227123)
1. Noninvasive characterization of the effect of varying PLGA molecular weight blends on in situ forming implant behavior using ultrasound imaging.
Solorio L; Olear AM; Hamilton JI; Patel RB; Beiswenger AC; Wallace JE; Zhou H; Exner AA
Theranostics; 2012; 2(11):1064-77. PubMed ID: 23227123
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive characterization of in situ forming implants using diagnostic ultrasound.
Solorio L; Babin BM; Patel RB; Mach J; Azar N; Exner AA
J Control Release; 2010 Apr; 143(2):183-90. PubMed ID: 20060859
[TBL] [Abstract][Full Text] [Related]
3. Characterization of formulation parameters affecting low molecular weight drug release from in situ forming drug delivery systems.
Patel RB; Carlson AN; Solorio L; Exner AA
J Biomed Mater Res A; 2010 Aug; 94(2):476-84. PubMed ID: 20186771
[TBL] [Abstract][Full Text] [Related]
4. Effect of injection site on in situ implant formation and drug release in vivo.
Patel RB; Solorio L; Wu H; Krupka T; Exner AA
J Control Release; 2010 Nov; 147(3):350-8. PubMed ID: 20728486
[TBL] [Abstract][Full Text] [Related]
5. Effect of implant formation on drug release kinetics of in situ forming implants.
Suh MS; Kastellorizios M; Tipnis N; Zou Y; Wang Y; Choi S; Burgess DJ
Int J Pharm; 2021 Jan; 592():120105. PubMed ID: 33232755
[TBL] [Abstract][Full Text] [Related]
6. Concomitant monitoring of implant formation and drug release of in situ forming poly (lactide-co-glycolide acid) implants in a hydrogel matrix mimicking the subcutis using UV-vis imaging.
Sun Y; Jensen H; Petersen NJ; Larsen SW; Østergaard J
J Pharm Biomed Anal; 2018 Feb; 150():95-106. PubMed ID: 29216591
[TBL] [Abstract][Full Text] [Related]
7. Lysozyme release and polymer erosion behavior of injectable implants prepared from PLGA-PEG block copolymers and PLGA/PLGA-PEG blends.
Vesna Milacic VM; Schwendeman SP
Pharm Res; 2014 Feb; 31(2):436-48. PubMed ID: 23959854
[TBL] [Abstract][Full Text] [Related]
8. Asenapine maleate in situ forming biodegradable implant: an approach to enhance bioavailability.
Avachat AM; Kapure SS
Int J Pharm; 2014 Dec; 477(1-2):64-72. PubMed ID: 25305379
[TBL] [Abstract][Full Text] [Related]
9. Influence of the microencapsulation method and peptide loading on poly(lactic acid) and poly(lactic-co-glycolic acid) degradation during in vitro testing.
Witschi C; Doelker E
J Control Release; 1998 Feb; 51(2-3):327-41. PubMed ID: 9685930
[TBL] [Abstract][Full Text] [Related]
10. Changes in morphology of in situ forming PLGA implant prepared by different polymer molecular weight and its effect on release behavior.
Astaneh R; Erfan M; Moghimi H; Mobedi H
J Pharm Sci; 2009 Jan; 98(1):135-45. PubMed ID: 18493999
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive characterization of in situ forming implant diffusivity using diffusion-weighted MRI.
Hopkins KA; Vike N; Li X; Kennedy J; Simmons E; Rispoli J; Solorio L
J Control Release; 2019 Sep; 309():289-301. PubMed ID: 31323243
[TBL] [Abstract][Full Text] [Related]
12. Reverse engineering of Perseris and development of compositionally equivalent formulations.
Wang X; Bao Q; Wang R; Wan B; Wang Y; Qin B; Burgess DJ
Int J Pharm; 2023 May; 639():122948. PubMed ID: 37044228
[TBL] [Abstract][Full Text] [Related]
13. In situ forming risperidone implants: Effect of PLGA attributes on product performance.
Wang X; Bao Q; Wang R; Kwok O; Maurus K; Wang Y; Qin B; Burgess DJ
J Control Release; 2023 Sep; 361():777-791. PubMed ID: 37591464
[TBL] [Abstract][Full Text] [Related]
14. In-situ forming PLGA implants: Towards less toxic solvents.
Ramos F; Willart JF; Neut C; Agossa K; Siepmann J; Siepmann F
Int J Pharm; 2024 May; 657():124121. PubMed ID: 38621617
[TBL] [Abstract][Full Text] [Related]
15. In-situ forming PLGA implants for intraocular dexamethasone delivery.
Bode C; Kranz H; Siepmann F; Siepmann J
Int J Pharm; 2018 Sep; 548(1):337-348. PubMed ID: 29981408
[TBL] [Abstract][Full Text] [Related]
16. In situ forming phase-inversion implants for sustained ocular delivery of triamcinolone acetonide.
Sheshala R; Hong GC; Yee WP; Meka VS; Thakur RRS
Drug Deliv Transl Res; 2019 Apr; 9(2):534-542. PubMed ID: 29484530
[TBL] [Abstract][Full Text] [Related]
17. In-situ forming composite implants for periodontitis treatment: How the formulation determines system performance.
Do MP; Neut C; Metz H; Delcourt E; Mäder K; Siepmann J; Siepmann F
Int J Pharm; 2015; 486(1-2):38-51. PubMed ID: 25791762
[TBL] [Abstract][Full Text] [Related]
18. Ultrasound-induced degradation of PLA and PLGA during microsphere processing: influence of formulation variables.
Reich G
Eur J Pharm Biopharm; 1998 Mar; 45(2):165-71. PubMed ID: 9704913
[TBL] [Abstract][Full Text] [Related]
19. Improved design and characterization of PLGA/PLA-coated Chitosan based micro-implants for controlled release of hydrophilic drugs.
Manna S; Donnell AM; Kaval N; Al-Rjoub MF; Augsburger JJ; Banerjee RK
Int J Pharm; 2018 Aug; 547(1-2):122-132. PubMed ID: 29857096
[TBL] [Abstract][Full Text] [Related]
20. Increasing Distribution of Drugs Released from In Situ Forming PLGA Implants Using Therapeutic Ultrasound.
Manaspon C; Hernandez C; Nittayacharn P; Jeganathan S; Nasongkla N; Exner AA
Ann Biomed Eng; 2017 Dec; 45(12):2879-2887. PubMed ID: 28929267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
